Nxera Pharma Co., Ltd.
Received USD 10 Million Milestone in Drug Discovery Collaboration Targeting Neurological Diseases with AbbVie
Nexera Pharma has received a USD 10 million milestone from the collaboration with AbbVie and holds rights to up to USD 1.2 billion in milestones and royalties.
Key Figures
- Milestone Received Amount: USD 10 million (approx. JPY 1,595 million)
- Maximum Total Milestones: USD 1.2 billion (approx. JPY 191.4 billion)
- Initial Development Milestone Rights: Up to USD 40 million (approx. JPY 6,380 million)
AI要約
Progress in Drug Discovery Collaboration and Milestone Receipt
Nexera Pharma Inc. has achieved its third significant milestone during the research phase within the multi-target drug discovery collaboration focused on neurological diseases with AbbVie, receiving USD 10 million (approx. JPY 1,595 million). This milestone is expected to be mostly recognized as revenue in 2026. The collaboration was established in 2022 and leverages Nexera Pharma's proprietary NxWave™ platform. The company holds rights to milestones totaling up to USD 1.2 billion and tiered royalties based on sales, demonstrating steady progress in the pipeline.
Outlook and Impact on Performance
The impact of this matter on the consolidated financial results for the fiscal year ending December 2026 has already been factored into the earnings guidance disclosed on February 13, 2026. Christopher Cargill, Representative Executive Officer and CEO, stated that the collaboration's outcomes contribute to expanding the pipeline's value, and the company will continue focusing on creating new therapeutic candidates addressing unmet medical needs in the neurological disease field.
Nexera Pharma Inc.
Company overview · Stock price · Financial data · All IR
